Summary of KalVista Pharmaceuticals FY Conference Call Company Overview - **Company**: KalVista Pharmaceuticals (NasdaqGM: KALV) - **Product**: Ekterly, the first and only oral therapy for the on-demand treatment of hereditary angioedema (HAE) attacks, approved in July 2025 [2][4] Key Points and Arguments Product Launch and Performance - **Launch Success**: Ekterly's commercial launch has exceeded expectations, with positive feedback from physicians and patients [2][8] - **Patient Satisfaction**: Approximately 90% satisfaction reported among patients and physicians within the first 7 months of launch [8] - **Market Penetration**: The drug is attracting patients from existing on-demand therapies, particularly from Ruconest, and is seeing a higher-than-expected conversion rate [10][11] Clinical Data and Education - **Clinical Trials**: KalVista conducted the largest Phase 2 and Phase 3 trials in HAE, demonstrating strong efficacy and safety [3][4] - **Educational Efforts**: Extensive outreach to physicians and the patient community has established KalVista as a thought leader in HAE treatment [5][6] Patient Support Services - **QuickStart Program**: Aimed at facilitating patient access to Ekterly, allowing for immediate shipment upon prescription approval [20][21] - **Refill Dynamics**: Patients are refilling Ekterly more frequently than anticipated, with an average of two cartons every two months, indicating higher usage rates [26][45] Market Dynamics - **High Burden Patients**: Approximately 20% of HAE patients experience two or more attacks per month, representing a significant market opportunity [34] - **Payer Dynamics**: Payers are currently accommodating high-burden patients, with limited restrictions on Ekterly access expected in the future [39] Future Growth and Strategy - **Pediatric Approval**: Plans to file for pediatric approval (ages 2-11) in Q3 2026, expanding the potential patient base [62] - **Short-term Prophylaxis**: Development of data to support Ekterly's use in short-term prophylaxis for procedures that may trigger attacks [63] - **Market Size**: The total addressable market (TAM) for HAE on-demand therapies is estimated at $1.5 billion, with current sales below $700 million due to a heavily genericized market [65][66] Financial Metrics - **Revenue Performance**: $35 million in Q4 and $49 million since launch, with refill revenue surpassing new patient starts [42][45] - **Gross-to-Net Expectations**: Anticipated gross-to-net ratios in the high teens to low twenties, consistent with industry standards [50] Additional Important Insights - **Community Engagement**: The patient ambassador program aims to connect patients with others who have similar experiences, enhancing understanding and comfort with Ekterly [58] - **Competitive Landscape**: KalVista is focused on maintaining its first-mover advantage against competitors like Pharvaris by continuing to educate the market on Ekterly's benefits [59][61] This summary encapsulates the key insights from the conference call, highlighting KalVista Pharmaceuticals' strategic positioning, product performance, and future growth opportunities in the HAE market.

Core Insights - Pharming Group N.V. announced that 12 abstracts have been accepted for presentation at the ACAAI 2025 Annual Scientific Meeting, highlighting the company's commitment to advancing research in hereditary angioedema (HAE) and activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) [1][3]. Summary by Category Clinical Data - Five posters will present positive clinical, economic, and comparative data for RUCONEST® in the treatment of on-demand hereditary angioedema (HAE) [2]. - Seven posters will focus on the real-world effectiveness of Joenja® (leniolisib), including results from the Phase III pediatric trial and insights into the burden faced by pediatric patients and caregivers dealing with APDS [2]. Presentation Details - Specific studies include an indirect treatment comparison of recombinant C1 inhibitor and Sebetralstat for HAE on-demand therapy, cost-effectiveness analysis, and patient-reported outcome measures across clinical trials [4][5]. - The presentations are scheduled for various dates and times during the ACAAI meeting, with ePosters accessible online for registered attendees [5]. Company Overview - Pharming Group is a biopharmaceutical company focused on developing innovative medicines for rare diseases, with a significant presence in both the U.S. and Europe [14].

DAW N Z E R AT M F DA A P P R OVA L N a s d a q : I O N S August 2025 Forward-Looking Statements This presentation includes forward-looking statements regarding the therapeutic and commercial potential of DAWNZERA (donidalorsen), Ionis' technologies, and Ionis' other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to cer ...

Confidential 1 Corporate Presentation November 2021 Forward Looking Statements This presentation and various remarks we make during this presentation contain forward-looking statements of Astria Therapeutics, Inc. ("Astria," the "Company," "we", "our" or "us") within the meaning of applicable securities laws and regulations, including statements with respect to: our future expectations, the potential benefits of the merger between the Company and Quellis Biosciences, Inc. (the "Merger"); our cash runway; th ...